Sign in
UPB Stock Price, Chart, Stats & News
Upstream Bio, Inc.
Save
Upstream Bio, Inc. (UPB) does not currently pay a dividend.
282.44M
Market cap
–
Current P/E
–
Forward P/E
UPB chart
Fundamentals
Gross margin | 96.92% |
Operating margin | -5618.82% |
Pretax margin | -5026.03% |
Net margin | -5026.03% |
Effective tax rate | – |
ROA | -40.55% |
ROE | -36.48% |
D/E | 0.00x |
Interest coverage ratio | – |
UPB valuation
P/E | – |
P/S | 165.32x |
P/B | 1.38x |
P/CF | -3.53x |
P/FCF | -3.54x |
P/OCF | -3.53x |
PEG | 0.20x |
EV multiple | -3.67x |
About
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
Similar securities
Based on sector and market capitalization
Report issue